WeightWatchers is struggling. Launched in the early 1960s, the brand grew by helping members shed pounds through behavioural change programmes. Then, GLP-1 anti-obesity drugs hit the market, long-time spokesperson and board member Oprah Winfrey announced her departure, and the company’s credit rating was downgraded. FT reporter Anna Mutoh examines whether WeightWatchers’ latest strategy can produce the turnaround investors are hoping for.
Clip from Lionsgate Television
- - - - - - - - - - - - - - - - - - - - - - - - - -
For further reading:
WeightWatchers faces an era when weight loss comes in a syringe
Behold the Ozempic effect on business
The race to develop the next generation of weight-loss drugs
- - - - - - - - - - - - - - - - - - - - - - - - - -
On X, follow Anna Mutoh (@anna_mutoh) and Michela Tindera (@mtindera07), or follow Michela on LinkedIn for updates about the show and more.
Read a transcript of this episode on FT.com
Hosted on Acast. See acast.com/privacy for more information.
The wrinkle in Shein’s IPO plans
Can anyone afford an NBA team?
Best Of: Inside a hedge fund disaster
Why auditors are missing red flags
Introducing Untold: Power for Sale
Dispatch from Omaha: Berkshire after Warren Buffett
Coming soon: China, the new tech superpower
Was the Archegos implosion illegal?
How shale rewrote the global oil order
When M&A goes wrong
Inside the battle for America’s West
Coming soon: The Five Minute Investor from Money Clinic
A surprising winner in the US-China chip wars
A radical change for the US Treasury market
Listener mailbag with the Unhedged podcast
Are penny stocks getting the memestock treatment?
How JPMorgan thrived amid a banking crisis
Is OpenAI’s business model sustainable?
Hedge fund pioneers face signs of a reckoning
Create your
podcast in
minutes
It is Free
The emPOWERed Half Hour
FT News Briefing
Money Clinic with Claer Barrett
FT World Weekly
FT News in Focus
FT Banking Weekly